Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study
…, A Stang, S Schmiedel… - Annals of internal …, 2020 - acpjournals.org
Background: The new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 210 000 deaths worldwide. However, little is known about …
has caused more than 210 000 deaths worldwide. However, little is known about …
Frequent neurocognitive deficits after recovery from mild COVID-19
…, F Ufer, A Hadjilaou, S Schmiedel… - Brain …, 2020 - academic.oup.com
Neuropsychiatric complications associated with coronavirus disease 2019 caused by the
Coronavirus SARS-CoV-2 (COVID-19) are increasingly appreciated. While most studies have …
Coronavirus SARS-CoV-2 (COVID-19) are increasingly appreciated. While most studies have …
A case of severe Ebola virus infection complicated by gram-negative septicemia
…, AW Lohse, MM Addo, S Schmiedel - New england journal …, 2014 - Mass Medical Soc
<p id="p001">Ebola virus disease (EVD) developed in a patient who contracted the disease
in Sierra Leone and was airlifted to an isolation facility in Hamburg, Germany, for treatment. …
in Sierra Leone and was airlifted to an isolation facility in Hamburg, Germany, for treatment. …
Phase 1 trials of rVSV Ebola vaccine in Africa and Europe
…, J Schmidt-Chanasit, S Schmiedel… - … England Journal of …, 2016 - Mass Medical Soc
Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
Clinical management of Ebola virus disease in the United States and Europe
…, AM Liddell, T Wolf, P Vetter, S Schmiedel… - … England Journal of …, 2016 - Mass Medical Soc
Background Available data on the characteristics of patients with Ebola virus disease (EVD)
and clinical management of EVD in settings outside West Africa, as well as the …
and clinical management of EVD in settings outside West Africa, as well as the …
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
…, O Witzke, T Wolf, MJGT Vehreschild, S Schmiedel… - Nature Cancer, 2023 - nature.com
Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+ T Regulatory Cells Correlates with …
…, K Colberg, S Frerk, D Babikir, S Schmiedel… - Journal of …, 2011 - Am Soc Microbiol
There are conflicting data about the frequency and role of regulatory T cells (Tregs) during
the course of HIV infection. Peripheral blood of a large cohort of HIV-infected patients (n = 131…
the course of HIV infection. Peripheral blood of a large cohort of HIV-infected patients (n = 131…
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
…, R Neumann, R Fux, S Schmiedel… - The Lancet Infectious …, 2020 - thelancet.com
Background The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a
respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public …
respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public …
Unique human immune signature of Ebola virus disease in Guinea
…, M Lago, A Negredo, L Franco, P Anda, S Schmiedel… - Nature, 2016 - nature.com
Despite the magnitude of the Ebola virus disease (EVD) outbreak in West Africa, there is still
a fundamental lack of knowledge about the pathophysiology of EVD 1 . In particular, very …
a fundamental lack of knowledge about the pathophysiology of EVD 1 . In particular, very …
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany
…, H Sudeck, GD Burchard, S Schmiedel - The Journal of …, 2011 - academic.oup.com
A needlestick injury occurred during an animal experiment in the biosafety level 4
laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) …
laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) …
